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Abstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. 
During those years, researchers and clinicians have developed a growing base of knowledge on 
the benefits of losartan, particularly for hypertension and renal disease. These benefits include 
decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hyperten-
sion, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many 
of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and 
pharmacodynamic characteristics and effects that are unique and are not a class effect. For 
example, a shorter duration of action is seen with this first ARB compared with other more 
recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and 
attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other 
ARBs. This review presents the physiological effects of losartan on the kidney and discusses 
relevant clinical outcomes.
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Losartan was first Food and Drug Administration (FDA) approved in 1995 as an antihy-
pertensive and is scheduled for generic release in April 2010.1 During the past 15 years, 
there has been great progress in understanding the effects of angiotensin II (AII) in the 
kidney and the benefits of blockade of AII at the AT1 receptor. Although losartan is now 
one of many angiotensin receptor blockers (ARBs), it was the first clinically used and 
has significantly contributed to both the physiologic understanding of AII and the clini-
cal benefit of AII blockade. This review will present the renal effects of AT1 receptor 
blockade and the clinical benefits, which have been seen with losartan. It is understood 
that many of the effects of losartan are a class effect; however, there are 2 effects that are 
novel to losartan: uricosuria and effects on thrombosis. Many articles have been written 
about losartan; in fact, a Medline search for “losartan” returned 6,396 articles, “losartan 
and the kidney” 1,419, “losartan and hypertension” 2,596, and “losartan and chronic 
kidney disease” 262. It would be impossible to detail results of all of these. Instead an 
overview of the benefits of losartan is presented. Because vascular disease is a major 
morbidity and mortality for kidney disease patients, important outcome findings with 
congestive heart failure and stroke prevention are also included. Although many would 
consider losartan the weakest of the class, it has no doubt lead to impressive findings 
and important outcomes.
Pharmacokinetics and FDA approval
Losartan is a nonpeptide molecule, which is a competitive antagonist with selective binding 
to AT1 receptors. Losartan has an oral bioavailability of 33% and has significant first-pass International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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metabolism using the cytochrome P450 system. Specifically, 
the cytochrome P450 enzymes, CYP2C9 and CYP3A4, are 
involved with the biotransformation to the active metabolites 
that are 10–40 times more potent by weight than the parent 
molecule losartan. The metabolites appear to be a reversible, 
noncompetitive inhibitor of the AT1 receptor. Elimination 
of losartan is approximately 40% in urine and 60% in feces. 
Losartan and its metabolites are highly protein bound, mainly 
to albumin, but other plasma proteins bind them leaving only 
1.3% and 0.2% free, respectively. The half-life of losartan is 2 
hours with the terminal half-life of the metabolites being lon-
ger at 6–9 hours.2 When dosed twice a day, its blood pressure 
lowering is equivalent to other ARBs given once a day.
Losartan has FDA approval for the treatment of hyperten-
sion either alone or in combination with other antihyperten-
sives, including diuretics. In patients with both hypertension 
and left ventricular hypertrophy (LVH), it is indicated to 
reduce the risk of stroke (although the benefit in black patients 
was not seen in the supporting trial). The third indication is for 
diabetic nephropathy in patients with type 2 diabetes with an 
elevated serum creatinine and proteinuria in order to reduce the 
occurrence of doubling of serum creatinine or end-stage renal 
disease.2 Although these are the FDA-approved indications for 
the clinical use of losartan, as discussed below, the benefit of 
losartan has been tested in multiple other settings.
Effects of losartan on the kidney
AT1 plays a significant role in the hemodynamic, electrolyte, 
and fluid balance regulation of the kidneys. Xu, Mao, Liu, 
WU and Xu have previously carefully outlined the intrarenal 
renin–angiotensin–aldosterone system (RAS).3 In order to 
understand the multiple effects of losartan, it is critical to 
understand the local effects of the RAS system, particularly 
the effects of AT1 receptors. The concentration of AII is 
about 1,000 times higher in the kidney than in the circulation. 
All the key elements of the RAS system have been demon-
strated within various portions of the kidney, and its action 
have shown both paracrine and autocrine regulation. The AT1 
receptor has been detected in almost all parts of the nephron.4 
The AII activation of the AT1 receptor leads to upregulation of 
angiotensinogen, rennin, and angiotensin-converting enzyme 
(ACE). Thus, losartan by blocking the AT1 receptor leads 
to decreased intrarenal AII by blocking this upregulation.5 
Table 1 shows the effects of losartan on the kidney.
Blocking AT1 receptors in the kidney have multiple 
effects that can be beneficial. For instance, AII causes 
  contraction of mesangial cells leading to a decrease in 
  glomerular filtration rate (GFR), which can be blocked by 
losartan. However, the overall effect of losartan on GFR can 
be variable, depending on whether the blood pressure remains 
in the renal autoregulatory range. If the blood pressure is 
within this range, losartan is associated with an increase in 
GFR.6 However, with low blood pressure, it may be associ-
ated with decreased, increased, or unchanged GFR.7
In pathologic states, AT1 blockade improves the impaired 
autoregulation induced by chronic abnormal activation 
of RAS.8 AT1 receptor blockade has experimentally been 
shown to decrease renal fibrosis as AII promotes deposition 
of extracellular matrix in the mesangium. AT1 activation also 
increased TGF-β1 that activates fibroblasts and increases 
their transformation to myoblasts, which in turn leads to 
fibrosis.9,10 Losartan may also be able to decrease inflam-
mation by decreasing leukocyte proliferation and blocking 
upregulation of adhesion molecules.11 Because of these renal 
effects, it is not surprising that outcome studies have shown 
a benefit to blocking AT1 receptors with losartan.
Losartan and uric acid
A unique effect of losartan (compared to other AT1 receptor 
blockers) is to reduce proximal tubular reabsorption of uric 
acid leading to increased uric acid excretion and decreased 
serum uric acid concentrations.12 The magnitude of changes 
in uric acid levels has been variable in studies where losar-
tan is used as an antihypertensive.13–17 These decreases in 
Table 1 Renal effects of blocking AT1 receptors
Renal hemodynamics
  variable effect on GFR depending on blood pressure
  Improved autoregulation
Renal tubular function
  Proximal tubules
    Reduction of sodium and fluid reabsorption
    Normalizes acidification and bicarbonate reabsorption
  Distal tubules
    Normalizes water, electrolytes, and acid – base balance
    Collecting ducts
    Blocks stimulation of aquaporin 2 and urinary concentration
Glomerular permselectivity
  Improves charge selectivity of the glomerular basement membrane
  Decreases radical oxygen species
    Protects the size selectivity of the GBM by blocking AII-induced 
collagen synthesis
  Ameliorates podocyte destruction
Renal fibrosis
  Blocks eCM deposition in the mesangium
  Attenuates fibroblast proliferation and transformation
Inflammation
  Blocks proliferation of leukocytes
  Blocks upregulation of adhesion molecules
Abbreviations: eCM, extracellular matrix; GBM, glomerular basement membrane; 
GFR, glomerular filtration rate; AII, angiotensin II.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Lessons from losartan
uric acid levels have also been seen in patients with renal 
  insufficiency. Interestingly, patients with end-stage renal 
disease on hemodialysis also had a decrease in uric acid 
levels even though urinary losses could not explain this.18 
The clinical implication of decreasing uric acid levels as a 
mechanism to decrease cardiovascular risk is unknown.
Hyperuricemia is a significant post-transplant compli-
cation in patients treated with cyclosporine. Kamper and 
Nielsen showed that losartan treatment in hypertensive 
post-transplant patients decreased fractional excretion of 
uric acid by 17% and decreased plasma uric acid by 8%.19 
In a recent study by Zhu et al20 66 Han Chinese postrenal 
transplant patients were enrolled at least 3 months post 
transplant and with stable renal function. Thirty-four were 
treated for 6 months with losartan 50 mg/d and 32 served as 
controls. Uric acid levels significantly decreased, particularly 
in those with hyperuricemia. It must be noted that 9 patients 
in the treatment group and 5 in the control group withdrew 
due to acute renal insufficiency, anemia, acute rejection, or 
poor compliance. A second finding of this study was that 
hematocrit levels decreased in the losartan-treated patients, 
particularly in those with post-transplant erythrocytosis.
Losartan and antiplatelet action
Losartan exerts an antiplatelet action by blockade of throm-
boxane A2 (TxA2) receptors.21 In the animal model using 
the stroke-prone spontaneously hypertensive rat, losartan 
has been shown to reduce platelet activation and aggrega-
tion while causing vasodilation.22,23 In this model, this was 
shown not to be a class effect of ARBs as candesartan and 
valsartan had no effect on platelet activation.23 In humans, 
losartan and irbesartan have demonstrated this effect, while at 
higher doses, valsartan and telmisartan have inhibited platelet 
aggregation.24–26 Candesartan does not appear to influence 
platelet aggregation.27 In the usual therapeutic dosing range, 
losartan has been shown to be effective. This effect is not 
seen with ACE inhibitors.
Losartan and proteinuria
Reduction of proteinuria is associated with stabilization of renal 
disease or slowing of its progression. This has been seen in 
both diabetic and nondiabetic nephropathy and is both depen-
dent and independent of blood pressure lowering.28 Losartan 
has also been shown to decrease proteinuria in nondiabetic 
nephropathies. For instance, losartan at 50 mg/d significantly 
decreased proteinuria in a small group of patients with biopsy-
proven AA amyloidosis treated for 12 months compared with 
control patients with similar mean arterial blood pressure.29 
In a larger trial of hypertensive patients, losartan significantly 
decreased proteinuria more than amlodipine in patients with 
higher and lower baseline levels of proteinuria.30 An additional 
example is a reduction of proteinuria in normotensive patients 
with focal segmental glomerulosclerosis.31
Losartan and renal protection
Blood pressure reduction is associated with renal protection 
and slowing of progression of chronic kidney disease (CKD). 
Losartan lowers blood pressure alone and in combination with 
other antihypertensives.32,33 Blood pressure reduction is only 
part of the benefit of RAS blockade for renal protection. ARBs 
have been shown to provide antihypertensive and renoprotec-
tive effects similar to those achieved with ACE inhibitors. The 
Renalprotection of Optimal Antiproteinuric Doses (ROAD) 
trial showed that titration to maximal   antiproteinuric effect of 
benazepril or losartan beyond usual antihypertensive ranges 
did not show increased blood pressure reduction but was asso-
ciated with a significant reduction in the risk of doubling of the 
serum creatinine concentration by 49% and 50%, respectively, 
at 3.7 years. This was associated with a decrease in end-stage 
renal disease (ESRD) risk by 47% with both drugs.34
There has been 1 large trial to show the outcome benefit 
of losartan in type 2 diabetes patients. In this trial, 1,513 
individuals with a mean creatinine of 1.9 mg/dL were enrolled 
in the The Reduction of End Points in Type 2 Diabetes with 
the Angiotensin II Antagonist Losartan (RENAAL) study. 
During a follow-up of 3.4 years, treatment with losartan 
reduced the incidence of a doubling of the serum creatinine 
concentration (risk reduction, 25%; P = 0.006) and ESRD 
(risk reduction, 28%; P = 0.002). This protection was larger 
than what would be expected with blood pressure reduction 
alone and that these benefits exceeded those attributable to 
measured reductions in blood pressure.35 The most significant 
risk factor for progression was the degree of proteinuria at 
baseline and at 6 months.36–38 At 6 months, losartan reduced 
proteinuria by 28% while the placebo was associated with a 
4% increase in proteinuria.36
The combination of ACE inhibitor with ARB has 
been shown to have a significant benefit in reduction of 
proteinuria.39,40 However, these and other studies have used 
submaximal dosing of each drug leaving questions as to 
whether the addition of an ACE inhibitor to doses of an 
ARB, which is at maximal antiproteinuric effect (or vice 
versa) would be of added benefit. Unfortunately, there is 
insufficient evidence to show that combination treatment 
slows the progression of renal disease. Initially, the combina-
tion treatment of angiotensin-II receptor blocker and ACE International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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inhibitor in nondiabetic renal disease (COOPERATE) study 
was thought to show this benefit; however, due to significant 
questions regarding this study, it was later retracted.41
The first effective, oral, direct renin inhibitor, aliskiren, has 
been evaluated in combination with the first ARB. A trial of 
aliskerin plus losartan in type 2 diabetic nephropathy showed 
a greater significant reduction of 20% in proteinuria compared 
with losartan alone. The outcome benefit on slowing the pro-
gression of renal disease has not yet been shown.42
Losartan and heart failure  
outcome trials
Blockade of the RAS system has been shown to improve 
survival and hospitalizations in heart failure patients being 
treated with ACE inhibitors. These benefits of treating with 
losartan have also been evaluated. The first trial, Evaluation 
of Losartan in the Elderly (ELITE) compared treatment of 
NYHA class II–IV heart failure patients (age 65 or older) 
treated with captopril (up to 50 mg, 3 times a day) and losar-
tan (up to 50 mg a day) treated for 47 weeks. The primary 
end point was a worsening renal function. There were no 
significant changes in renal function. It is important to note 
that the event rate was lower than anticipated, and therefore, 
the study may not have been powered to show a significant 
difference. As a secondary end point, mortality was decreased 
46% in the losartan-treated patients.43 To show superiority 
of losartan, a second trial ELITE II enrolled 3,152 patients 
(age 60 or older) with NYHA class II–IV heart failure and 
a left ventricular ejection fraction of 40% or less. Patients 
were treated with either losartan 50 mg a day or captopril 
50 mg 3 times a day. There were no statistical differences 
between the 2 treatment arms regarding the primary end 
points, including sudden death and the composite of mortal-
ity and hospitalizations. Losartan was better tolerated than 
captopril with fewer patients discontinuing prematurely 
owing to adverse events (not counting death).44
These 2 studies were conducted with losartan 50 mg a 
day. Higher doses of losartan are associated with further 
decrease in blood pressure, and with increases up to l50 mg 
of losartan, there is increasing renin levels and circulating 
AII.45 The Effects of high-dose versus low-dose losartan on 
clinical outcomes in patients with heart failure (HEAAL 
study) was a randomized, double-blind trial of losartan of 
150 mg compared with losartan of 50 mg in patients with 
heart failure, who were intolerant of ACE inhibitor therapy 
for a median follow-up of 4.7 years. The primary end point 
was death or admission for heart failure. With an intention 
to treat analysis, there was no difference in deaths, but there 
was a significant decrease in hospitalizations for heart   failure 
with fewer hospitalizations with the higher dose. Renal 
impairment, hypotension, and hyperkalemia were also higher 
in the higher dose group, but there was not an increase in 
discontinuation rate in this group.46
Losartan intervention for endpoint 
reduction trial as a look at losartan 
benefits
The Losartan Intervention for Endpoint Reduction (LIFE) 
trial was a double-blind study of 9,193 hypertensive patients 
between the ages of 55 and 80, who were at high risk. The 
entry criteria included hypertension and LVH (determined by 
ECG). Participants were randomly assigned to either losartan 
or atenolol. Doses were increased and hydrochlorothiazide 
or other medications were added to obtain a target blood 
pressure of less than 140/90 mmHg. Both medications were 
started at 50 mg and titrated to 100 mg as needed. The primary 
end points were occurrence of cardiovascular death, myocar-
dial infarction, or stroke, and the composite end point was any 
of these events. Losartan was associated with a significantly 
decreased incidence of the primary composite end point. This 
was primarily due to a decrease in fatal and nonfatal stroke. 
Blood pressure control was similar in the 2 groups. This 
stroke benefit was not seen in African Americans.47
Substudies of this outcome trial have provided a number 
of additional benefits of losartan therapy in this population. 
Findings show a benefit of losartan over atenolol in surrogate 
markers, as well as in clinical outcomes. For example, losartan-
treated individuals had significant LVH regression48,49 and 
decrease in left atrial size50,51 and decreased BNP.52,53 They also 
had decreased platelet aggregation, decreased serum uric acid,54 
improved insulin sensitivity,55 attenuated decline in HDL,56 
and decreased proteinuria.57 All of these would be significant 
surrogate markers for improved cardiovascular risk. Clinically 
significant findings were decreased incidence of atrial fibrilla-
tion58 and new onset diabetes.47,59 These may help explain the 
positive outcome of the LIFE trial and may prove useful to 
patients with chronic kidney disease after further studies.58
The economic impact of losartan
Several studies have looked at the economic impact of treating 
patients with type 2 diabetes with losartan using the RENAAL 
trial for analysis. A cost benefit was seen after 2–2.5 years, 
and at 4 years of follow-up, the cost savings by averting days 
with ESRD was $5,300/patient (95% CI, US $950–9,600).60 
A Mexican cost assessment using the RENAAL trial showed 
that treatment with losartan led to greater life expectancy and International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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lower cost.61 Using the LIFE trial, a Netherland’s study noted 
that the medication costs for atenolol was $64 lower than for 
losartan, but the net cost per life year gained was only $1,083, 
well under the cost that is usually considered worth utilizing 
a treatment.62 Losartan has been a preferred drug on most 
managed care medication lists, and now that it will soon be 
generic, the cost benefit will increase.
Conclusion
Over the past 15 years, there has been a wide variety of studies 
conducted with losartan. It has shown benefit in controlling 
hypertension, decreasing proteinuria, slowing the progression 
of type 2 diabetic nephropathy, and decreasing the risk of 
stroke in certain populations. In addition, favorable surrogate 
markers such as decreased platelet aggregation, decreased 
uric acid, decreased proteinuria, and regression of LVH have 
also been documented. For a first in class medication, which 
is touted as being a weaker angiotensin receptor blocker, it 
has shown remarkable outcomes. Although, pharmacoki-
netic differences, particularly the shorter half-life, should 
be kept in mind, this drug should remain an active part of 
our armamentarium.
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